OBJECTIVES: Voriconazole exhibits non-linear pharmacokinetics in adults and is said to be mainly metabolized by CYP2C19 and CYP3A4 to voriconazole-N-oxide. The aim of this study was to obtain data on steady-state pharmacokinetics after dosing for at least 14 days in patients taking additional medication and in vivo data on metabolites other than voriconazole-N-oxide. PATIENTS AND METHODS: Thirty-one patients receiving voriconazole as regular therapeutic drug treatment during hospitalization participated in this prospective study. Pharmacokinetic profiles were obtained for the 12 h (dosing interval) after the first orally administered dose (400 mg) or (if possible and) after an orally administered maintenance dose (200 mg) following intake for at least 14 days (n = 14 after first dose; n = 23 after maintenance dose). Blood and urine samples were collected and the concentrations of voriconazole and three of its metabolites (the N-oxide, hydroxy-voriconazole and dihydroxy-voriconazole) were determined, as well as the CYP2C19 genotype of the patients. All other drugs taken by the participating patients were evaluated. RESULTS: A high variability of exposure (AUC) after the first dose was slightly reduced during steady-state dosing for voriconazole (82% to 71%) and the N-oxide (86% to 56%), remained high for hydroxy-voriconazole (79%) and even increased for dihydroxy-voriconazole (97% to 127%). In 16 of the 22 steady-state patients, trough plasma concentrations were <2 μg/mL. N-oxide plasma concentrations during steady state stayed almost constant. Hydroxylations of voriconazole seem to be quantitatively more important in its metabolism than N-oxidation. CONCLUSIONS: High variability in voriconazole exposure, as well as low steady-state trough plasma concentrations, suggest that the suggested steady-state dosage of 200 mg twice a day has to be increased to prevent disease progression. Therapeutic drug monitoring is probably necessary to optimize the voriconazole dose for individual patients.
OBJECTIVES:Voriconazole exhibits non-linear pharmacokinetics in adults and is said to be mainly metabolized by CYP2C19 and CYP3A4 to voriconazole-N-oxide. The aim of this study was to obtain data on steady-state pharmacokinetics after dosing for at least 14 days in patients taking additional medication and in vivo data on metabolites other than voriconazole-N-oxide. PATIENTS AND METHODS: Thirty-one patients receiving voriconazole as regular therapeutic drug treatment during hospitalization participated in this prospective study. Pharmacokinetic profiles were obtained for the 12 h (dosing interval) after the first orally administered dose (400 mg) or (if possible and) after an orally administered maintenance dose (200 mg) following intake for at least 14 days (n = 14 after first dose; n = 23 after maintenance dose). Blood and urine samples were collected and the concentrations of voriconazole and three of its metabolites (the N-oxide, hydroxy-voriconazole and dihydroxy-voriconazole) were determined, as well as the CYP2C19 genotype of the patients. All other drugs taken by the participating patients were evaluated. RESULTS: A high variability of exposure (AUC) after the first dose was slightly reduced during steady-state dosing for voriconazole (82% to 71%) and the N-oxide (86% to 56%), remained high for hydroxy-voriconazole (79%) and even increased for dihydroxy-voriconazole (97% to 127%). In 16 of the 22 steady-state patients, trough plasma concentrations were <2 μg/mL. N-oxide plasma concentrations during steady state stayed almost constant. Hydroxylations of voriconazole seem to be quantitatively more important in its metabolism than N-oxidation. CONCLUSIONS: High variability in voriconazole exposure, as well as low steady-state trough plasma concentrations, suggest that the suggested steady-state dosage of 200 mg twice a day has to be increased to prevent disease progression. Therapeutic drug monitoring is probably necessary to optimize the voriconazole dose for individual patients.
Entities:
Keywords:
dihydroxy-voriconazole; exposure variability; hydroxy-voriconazole; therapeutic drug monitoring; voriconazole-N-oxide
Authors: Eline W Muilwijk; Bart G J Dekkers; Stefanie S V Henriet; Paul E Verweij; Bregje Witjes; Astrid M L Oude Lashof; Geert H Groeneveld; Johannes van der Hoeven; Jan Willem C Alffenaar; Frans G M Russel; Frank van de Veerdonk; Roger J M Brüggemann Journal: Antimicrob Agents Chemother Date: 2017-08-24 Impact factor: 5.191
Authors: Woo J Moon; Erica L Scheller; Anupam Suneja; Jacob A Livermore; Anurag N Malani; Varsha Moudgal; Lisa E Kerr; Eric Ferguson; David M Vandenberg Journal: Clin Infect Dis Date: 2014-07-03 Impact factor: 9.079
Authors: Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett Journal: Clin Infect Dis Date: 2016-06-29 Impact factor: 9.079
Authors: J Kevin Hicks; Kristine R Crews; Patricia Flynn; Cyrine E Haidar; Calvin C Daniels; Wenjian Yang; John C Panetta; Deqing Pei; Jeffrey R Scott; Alejandro R Molinelli; Ulrich Broeckel; Deepa Bhojwani; William E Evans; Mary V Relling Journal: Pharmacogenomics Date: 2014-06 Impact factor: 2.533
Authors: Xia Li; Sebastian Frechen; Daniel Moj; Thorsten Lehr; Max Taubert; Chih-Hsuan Hsin; Gerd Mikus; Pertti J Neuvonen; Klaus T Olkkola; Teijo I Saari; Uwe Fuhr Journal: Clin Pharmacokinet Date: 2020-06 Impact factor: 6.447